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Abstract. 
 
Tight junctions are the most apical compo-
nents of endothelial and epithelial intercellular cleft. In 
the endothelium these structures play an important role 
in the control of paracellular permeability to circulating 
cells and solutes. The only known integral membrane 
protein localized at sites of membrane–membrane inter-
action of tight junctions is occludin, which is linked in-
side the cells to a complex network of cytoskeletal and 
signaling proteins. We report here the identification of a 
novel protein (junctional adhesion molecule [JAM]) that 
is selectively concentrated at intercellular junctions of 
endothelial and epithelial cells of different origins. Con-
focal and immunoelectron microscopy shows that JAM 
codistributes with tight junction components at the api-
cal region of the intercellular cleft. A cDNA clone en-
coding JAM defines a novel immunoglobulin gene 
superfamily member that consists of two V-type Ig 
domains. An mAb directed to JAM (BV11) was found 
to inhibit spontaneous and chemokine-induced mono-
cyte transmigration through an endothelial cell mono-
layer in vitro. Systemic treatment of mice with BV11 
mAb blocked monocyte infiltration upon chemokine ad-
ministration in subcutaneous air pouches. Thus, JAM is 
a new component of endothelial and epithelial junctions 
that play a role in regulating monocyte transmigration. 
Key words: endothelium • epithelium • monocyte • 
tight junctions • inflammation
 
I
 
t
 
 is currently believed that leukocytes leave the circula-
tion by first adhering to endothelial cells and then mi-
grating through the interendothelial junctions (32,
50). This last process implies the transient opening of in-
terendothelial contacts allowing leukocytes to transmi-
grate through the adjacent endothelial cells (16).
At least two types of cell to cell junctional structures
have been identified in the endothelium: adherens
 
 
 
junc-
tions (AJ)
 
1
 
 and tight junctions (TJ; 16, 45). These or-
ganelles present common features in endothelial (EC) and
epithelial cells. AJ are formed by clusters of transmem-
brane proteins belonging to the cadherin family linked in-
tracellularly to catenins (
 
b
 
-catenin, plakoglobin, p120),
which in turn promote anchoring to the actin cytoskeleton
(15, 26, 28, 31, 33, 35, 52).
The molecular organization of TJ is less understood.
The first transmembrane protein identified is occludin
(21), which is directly bound intracellularly to zonula oc-
cludens-1 (ZO-1), a member of the MAGUK family
(membrane-associated guanylate kinases; 22). A number
of other cytoplasmic proteins have been reported to be as-
sociated with the plaque structure underlying TJ, such as
ZO-2, 130-kD protein, 7H6 antigen, cingulin, symplekin
(34), and others (for review see references 3, 4, and 11).
How leukocytes traverse intercellular junctions and dis-
rupt their fine organization is still largely unknown. It was
found that PECAM-1 (platelet endothelial cell adhesion
molecule-1, CD31), a member of the immunoglobulin
gene superfamily (IgSF) located at interendothelial junc-
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tions, is required for leukocyte transmigration (7, 38, 55,
60). PECAM-1 is not associated with either AJ or TJ
structures (5).
To characterize further the molecular organization of
intercellular junctions in the endothelium and to define
their role in leukocyte transmigration, monoclonal anti-
bodies directed to mouse EC (56, 24) were used to screen
for antigens located at cell–cell contacts. A mAb, BV11,
was found to label endothelial and epithelial intercellular
junctions selectively in a region close to TJ. Expression
cloning revealed that BV11 recognizes a new member of
the IgSF (8, 29). Monocyte transmigration was inhibited
by mAb BV11 both in chemotaxis assays in vitro and in a
model of skin inflammatory reaction in vivo.
 
Materials and Methods
 
Cells
 
Mouse EC, 1G11, kindly provided by A.Vecchi (Mario Negri Institute,
Milan, Italy), were obtained from mouse lung microcirculation, main-
tained in DMEM (GIBCO BRL, Paisley, Scotland), supplemented with
10% FCS, 50 
 
m
 
g/ml endothelial cell growth supplement (prepared from
bovine brain), and 100 
 
m
 
g/ml heparin (Sigma Chemical Co, St. Louis,
MO), and used within passage 15 (17). H5V, a mouse EC line derived
from primary cultures of mouse heart endothelial cells immortalized by
polyoma virus middle T antigen, were also provided by A.Vecchi and
characterized in detail elsewhere (25). Mouse epithelial cells (PDV),
kindly provided by A. Cano (Instituto de Investigaciones Biomedicas,
Madrid, Spain), were skin keratinocytes isolated and cultured as previ-
ously described (23). Monocytes were obtained from the peripheral blood
of normal healthy donors as reported in detail (14). CHO cells and SP2/0
were obtained from American Type Culture Collection (Rockville, MD).
CHO cells were transfected by calcium phosphate precipitation method
with 20 
 
m
 
g of pECE-junctional adhesion molecule (JAM) and 2 
 
m
 
g of pB-
SpacDp plasmids as previously described (10). Then, cells were cultured
in selective medium with puromycin (Sigma Chemical Co.), and the re-
sulting resistant colonies were isolated and tested for BV11 antigen
(JAM) expression by immunofluorescence staining and immunoprecipita-
tion analysis. Positive cells were cloned and expanded for further studies
as described (10).
Vascular endothelial (VE)-cadherin and N-cadherin transfectants were
produced and cultured as reported (40). VE-cadherin truncated mutant
was produced and characterized previously (39). This mutant lacks the in-
tracellular domain responsible for binding to catenins and to the actin cy-
toskeleton.
 
Antibodies
 
mAbs BV11 and BV12 were generated in our laboratory following a pre-
viously described procedure (56). In brief, male Lewis rats were immu-
nized with H5V endothelial cells with successive intraperitoneal injec-
tions. 3 d after the final boost, rat spleen cells were fused with the SP2/0
mouse myeloma cells and grown in selective medium.
 
 
 
Culture
 
 
 
superna-
tants of hybrid clones were screened for reactivity on H5V cells by an
ELISA test (56) and in immunofluorescence microscopy for their ability
to decorate intercellular contacts (36).
In further studies, the two mAbs were found to be positive in ELISA
for binding to a recombinant JAM (BV11 antigen, see below) Fc fusion
protein consisting of the NH
 
2
 
-terminal domain of the protein up to amino
acid 132, prepared and purified as described previously (19, 20). However,
by cross-competitive mAb-binding assay performed as described else-
where (37), BV12 was unable to inhibit radiolabeled BV11 binding. This
result strongly suggests that the two mAbs recognize a different epitope.
F(ab
 
9
 
) fragments of BV11 were prepared by standard procedures (41).
mAb MEC 14 to CD34 was kindly provided by A. Vecchi (24). Hybri-
doma-producing mAb MK 2.7 and mAb HB151 of the same isotype
(IgG2b) of BV11 were obtained from American Type Culture Collection
and used as controls.
The antibodies used in fluorescence microscopy were as follows: rat
mAb anti-E-cadherin DECMA (Sigma Chemical Co); rat mAb anti-ZO-1,
R40.76 kindly provided by B. Stevenson (University of Alberta, Canada;
reference 51); rabbit polyclonal antibody to cingulin by S. Citi (Università
di Padova, Padova, Italy; references 12 and 13); rabbit polyclonal antibody
to VE-cadherin by D. Vestweber (Institute of Cell Biology, Münster, Ger-
many; reference 9); and rabbit polyclonal antibody to 
 
b
 
-catenin (Trans-
duction Laboratories, Lexington, KY) and to occludin (Zymed Laborato-
ries, Inc., San Francisco, CA). As secondary antibodies, FICT-conjugated
Affinipure donkey anti–mouse, anti–rabbit, and TRICT-conjugated anti-
rat IgG with minimal cross-reaction with other species (Jackson Immu-
noResearch Laboratories, Inc., West Grove, PA) were used.
 
Fluorescence Flow Cytometric Analysis
 
Fluorescence flow cytometric analysis was performed by a FACStar
Plus™ apparatus (Becton Dickinson, Mountain View, CA) using an
FICT-conjugated goat anti–rat antiserum (mouse adsorbed;  Caltag Labo-
ratories, Burlingame, CA) as described in detail elsewhere (37).
 
Immunofluorescence Microscopy
 
Immunofluorescence analysis of antibody staining of the cells was as de-
scribed (36). In brief, cells were seeded on glass coverslips and grown to
confluence. Cells were then fixed with methanol for 3 min at 
 
2
 
20
 
8
 
C and
processed for indirect immunofluorescence microscopy.
For occludin staining, fixation was followed by subsequent incubation
with PBS-0,1% saponin (Sigma Chemical Co.) for 10 min, and with 0.1%
PBS, 0.5% saponin BSA for 10 min.
Coverslips were then mounted in Mowiol 4-88 and examined with an
immunofluorescence microscope (Axiophot; Carl Zeiss, Oberkochen,
Germany), and images were recorded on T MAX P3200 films (Eastman
Kodak Co., Rochester, NY).
Double-staining immunofluorescence was analyzed by confocal micros-
copy as described (42). Confocal microscopy was carried out on an MRC
1024 microscope (Bio-Rad Laboratories, Hercules, CA) equipped with a
krypton/argon laser. Noise reduction was achieved by Kalman filtering
during acquisition. The images were then recorded using a Focus Image-
recorder Plus image recorder (Focus Grafics, Inc., Grafite, Vimercate, It-
aly) and printed with a Seiko FII ColorPoint 2 (Grafite).
 
Immunohistochemistry
 
Organ specimens of adult and newborn mice and 14-d fetuses were ob-
tained and snap-frozen in isopentane cooled by liquid nitrogen to about
 
2
 
140
 
8
 
C as reported (24, 42). Frozen tissues were sectioned (7 
 
m
 
m) with a
CM 10800 cryostat (Leica Inc., Deerfield, IL), mounted on gelatine-
treated coverslips, briefly air-dried, and then fixed in 
 
2
 
20
 
8
 
C acetone for
10 min. After fixation, samples were washed twice with PBS and
quenched with 0.1 M glycine for 5 min.
For immunofluorescence confocal microscopy, primary antibodies
were incubated for 30 min followed by three 5-min washes with PBS be-
fore applying secondary antibodies for 30 min. After antibody binding,
samples were washed and then mounted. Confocal microscopy was car-
ried out as mentioned above (42).
For immunohistochemistry, sections were incubated with mAb BV11
after quenching, and immunostained using a biotinylated affinity-purified
anti-rat Ig (Sigma Chemical Co.) and streptavidin–HRP complexes
(Sigma Chemical Co). Samples were then counterstained with hematoxy-
lin, mounted, and analyzed as previously reported (24).
Immunoelectron microscopy was performed as previously described in
detail (57).
 
 
 
A rabbit antiserum raised by injecting a JAM recombinant
fragment consisting of the NH
 
2
 
 domain up to amino acid 132 under the
form of Fc fusion protein (19, 20) was used. Immunization procedures
were as described (20). The JAM recombinant fragments were produced
and purified as described previously (19, 20). The preimmune serum and
serum from immunized rabbits were tested in ELISA, immunofluores-
cence, and immunoprecipitation of JAM-CHO transfectants and cultured
endothelial cells (H5V; see below).
For immunogold labeling, ultrathin cryosections (50–100 nm–thick)
were collected over nickel grids and covered with 2% gelatin. After treat-
ment with 125 nM Na phosphate buffer (pH 7.4) supplemented with 0.1 M
glycine, the cryosections were exposed for 1 h at 37
 
8
 
C to the first antibody
diluted in phosphate–glycine buffer, and were then washed with the buffer
and decorated with anti IgG-coated gold particles (6 nm) exactly as de-
scribed elsewhere (57). 
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cDNA Expression Library and Cloning
 
cDNA expression library was constructed from a murine brain EC line
(bEnd.3; 19, 46, 47, 49). The cDNA library was oligo-dT primed bEnd.3
polyA
 
1
 
 RNA cloned into pCDM8. Three rounds of expression and pan-
ning yielded a single clone insert of 
 
z
 
2 kb. The pCDM8 inserts were res-
cued and subcloned in pBluescript vector and sequenced. The nucleotide
and deduced protein sequences were screened against the GenBank/
EMBL database using a FASTA/BLAST programs as implement on the
Internet resource.
 
Northern Blot
 
A multiple tissue Northern blot of mouse tissues (CLONTECH Laborato-
ries, Inc., Palo Alto, CA) containing 
 
z
 
2 
 
m
 
g of polyA
 
1
 
 
 
RNA per lane was
hybridized with a 1.3 XbaI fragment from the JAM cDNA clone, labeled
with [
 
32
 
P]dCTP by random priming as described (49). Hybridization was
performed at 65
 
8
 
C in ExpressHyb hybridization solution (CLONTECH
Laboratories, Inc.), washed according to the manufacturer’s protocols,
and autoradiographed on Kodak X-Omat AR film at 
 
2
 
70
 
8
 
C (49).
 
Immunoprecipitation and Immunoblot
 
Biotinylation and immunoprecipitation procedures are described else-
where (39). In brief, biotinylation of cell surface proteins was performed
using sulfonitrohydroxysuccinimidobiotin (Pierce Chemical Co., Rock-
ford, IL). Whole cell extracts were obtained from confluent cells and im-
munoprecipitated with protein A-Sepharose CL-4B (Pharmacia Biotech
Sverige, Uppsala, Sweden) coupled with rabbit anti–rat Ig (Sigma Chemi-
cal Co). Then samples were fractionated under reducing conditions on
7.5% SDS-PAGE gels, transferred to nitrocellulose membranes, and incu-
bated with HRP-streptavidin (Biospa Division, Milano, Italy). The HRP-
streptavidin was visualized using an enhanced chemiluminescence kit
(Amersham International, Buckinghamshire, United Kingdom) and auto-
radiography as previously described (39).
 
Cell Transmigration Assay
 
Monocyte chemotaxis through EC monolayers were performed as previ-
ously described (43). In brief, EC (IG11 and H5V) were cultured in Tran-
swell units (with polycarbonate filter, 8-
 
m
 
m pore; Costar Corp., Cam-
bridge, MA) to confluency. mAbs were added to EC monolayers for 30
min at 37
 
8
 
C, and were then kept throughout the transmigration assay.
Most of the experiments were done using purified BV11 mAb at 5 
 
m
 
g/ml
or hybridoma culture supernatant diluted 1:2, which are saturating con-
centrations by FACS analysis of both EC lines in suspension. All the other
mAbs were used at a concentration of 1:2 dilution of hybridoma culture
supernatant.
Washed monocytes (14) were labeled with 
 
51
 
Cr and then resuspended
at 1.8 
 
3 
 
10
 
6
 
 cells/ml in complete medium. An aliquot (750 
 
m
 
l/well) of radio-
labeled monocytes was added
 
 
 
and incubated for 60 min at 37
 
8
 
C. In some
experiments, the chemokines monocyte chemotactic protein-1 (MCP-1)
and MCP-3 (100 ng/ml; Peprotech, EC ltd., Rocky Hill, NJ) were added in
the lower chamber. In other experiments, EC monolayers were incubated
with lipopolysaccharide (LPS; 50 ng/ml in complete medium, 
 
Escherichia
coli
 
 055:B5; Sigma Chemical Co.) for 24 h, and were then washed before
monocyte addition.
At the end of the transmigration assay, nonadherent monocytes were
removed from the upper chamber (nonadherent fraction). Transmigrated
cells were both collected from the lower chamber medium and removed
by scraping the opposite face of the filter (migrated fraction). Adherent
monocytes together with the intact EC monolayer were then collected
from the polycarbonate membrane (adherent fraction). Radioactivity of
the three fractions was measured in a 
 
g
 
-counter (Beckman Instruments,
Inc., Fullerton, CA), and the number of cells in each fraction was quanti-
tated as described (43).
 
Permeability Assay
 
Permeability across cell monolayers was measured in Transwell units
(with polycarbonate filter, 0.4-
 
m
 
m pore; Costar Corp.) as previously de-
scribed (10). In brief, CHO transfectants were cultured to confluency for 5 d.
Then, culture medium was replaced with serum-free medium, and FITC-
dextran (1 mg/ml, average molecular mass of 38,900; Sigma Chemical Co.)
was added to the upper chamber. At 2 h, 100-
 
m
 
l aliquots were collected
from the lower compartment and assayed by fluorimetry (excitation wave-
length set at 492 nm and emission at 520 nm). In some experiments,
EGTA (5 mM final concentration) was added both to lower and upper
compartments for 1 h at the same time as dextran (10).
 
Air Pouch Model
 
The air pouch model procedure was described in detail elsewhere (18, 44).
In brief, after a period of adaptation, male CD1 mice (20–22 g) were anes-
thetized with ether, and 5 ml of sterile air was injected dorsally subcutane-
ously (day 0). 3 d later, pouches were reinjected with 3 ml of sterile air. On
day 5, animals received intravenous injection of either 100 
 
m
 
g or 200 
 
m
 
l of
mAb BV11, the same dose of an irrelevant purified mAb of the same iso-
type (clone HB151), or 200 
 
m
 
l of saline. On day 6, 1 
 
m
 
g of MCP-3 dis-
solved in 1 ml of carboxymethylcellulose (0.5% in saline; Fluka AG,
Buchs, Switzerland) was injected into the pouch. After 1 h, animals were
killed and the pouches were washed with 1 ml of saline (see Fig. 9). The la-
vage fluid was immediately cooled on ice, and the volume was recorded.
50-
 
m
 
l aliquots were used for cell counting after staining with erythrosin as
described (44).
 
Results
 
BV11 Antigen Distributes at Intercellular Junctions in 
Endothelial and Epithelial Cells
 
Fig. 1 reports the staining pattern of BV11 in cultured en-
dothelial cells and in intact vessels in vivo. The mAb deco-
rated cell–cell contacts in cultured EC (Fig. 1 
 
A
 
) in a way
similar to other junctional markers such as ZO-1 (Fig. 1 
 
B
 
)
or VE-cadherin (Fig. 1 
 
C
 
). In vivo, the mAb retained a
typical staining pattern at endothelial cell–cell contacts
(Fig. 1 
 
E
 
). At confocal microscopy, double-label immuno-
fluorescence analysis of tissue cryosections shows that in
vessels mAb BV11 distributed closely to TJ markers such
as cingulin (Fig. 1, 
 
D
 
–
 
F
 
) or occludin (not shown).
BV11 mAb was not specific for EC, but could recognize
epithelial cells of different origins (Fig. 2, 
 
A
 
–
 
F
 
). Higher
resolution analysis by confocal microscopy of cultured epi-
thelial cells revealed that the BV11 antigen is concen-
trated at the apical region of the intercellular cleft (Fig. 2,
 
B b
 
) in a way similar to TJ components such as ZO-1 or
occludin (not shown). Double-label immunofluorescence
analysis shows a good codistribution of the antigen with
TJ-specific components such as cingulin (Fig. 2, compare
 
A a
 
, 
 
B b
 
, and 
 
C c
 
) or occludin (not shown). In contrast, AJ
components such as 
 
b
 
-catenin or E-cadherin gave a more
diffuse staining along the intercellular cleft (34 and see be-
low), and at confocal microscopy did not codistribute with
BV11 antigen (not shown).
In tissue sections, BV11 was concentrated at the subapi-
cal domain of epithelial cell–cell contacts. A typical exam-
ple is reported in Fig. 2 (
 
D
 
–
 
F
 
), which shows mAb BV11
staining of the epithelium of mouse duodenum. BV11 was
restricted to a TJ-containing narrow apical region of the
cleft (Fig. 2 
 
E
 
). In contrast, AJ marker proteins such as
 
b
 
-catenin (Fig. 2 
 
D
 
) or E-cadherin (not shown) displayed a
more diffuse distribution all along the lateral wall of the
cells. Very little if any codistribution of BV11 and 
 
b
 
-cate-
nin could be observed (Fig. 2 
 
F
 
).
Immunogold labeling of ultrathin sections of the epithe-
lium of mouse duodenum revealed that BV11 antigen was
concentrated in the tight junction area, while no specific
staining was found in adherens junctions (
 
zonula adher-
ens)
 
 and desmosomes (Fig. 3, 
 
A
 
 and 
 
B
 
). In some sections
(see Fig. 3 
 
B
 
) the immunogold labeling was observed also 
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inside the cells, while the antibody recognizes the extracel-
lular domain of JAM. However, the majority of the golden
particles are within 25 nm, which is the approximate dis-
tance of antigen/immunogold particles.
A summary of the tissue distribution of BV11 is re-
ported in Table I. BV11 antigen was found in EC of differ-
ent origins. The staining appeared weaker in the high en-
dothelial venules of the lymph nodes (2, 27, 48). BV11
antigen was found in a wide variety of polar epithelia. In-
terestingly, lens cells, which are rich with AJ but lack TJ,
do not bind mAb BV11. BV11 staining was absent in both
hematopoietic precursors and mature circulating cells such
as leukocytes and erythrocytes, but was positive in mega-
karyocytes.
 
Identification and Cloning of BV11 Antigen
 
A single band of 36–41 kD under reduced conditions was
immunoprecipitated from epithelial cells and EC by BV11
mAb (Fig. 4 
 
A
 
). The apparent molecular mass was only
slightly modified under nonreduced conditions (36–43 kD,
not shown).
mAb BV11 was used to screen a cDNA expression li-
brary constructed from a murine brain EC line (bEnd.3) as
previously described (19, 46, 47, 49). The cDNA library
was oligo-dT primed bEnd.3 polyA
 
1
 
 RNA cloned into
pCDM8. Three rounds of expression and panning yielded
a single clone insert of 
 
z
 
2 kb. The nucleotide and deduced
amino acid sequence of this clone is shown in Fig. 5 
 
A
 
.
The cDNA insert consists of 2029 nucleotides. The open
reading frame gives a predicted polypeptide sequence of
300 amino acids, and has the typical feature observed in a
type I integral membrane protein. A potential initiating
methionine at nucleotide position 71 is followed by a puta-
tive signal peptide that may be cleaved between Leu 23
and Val 24, leaving 215 residues in the extracellular do-
main of the mature protein. A stretch of 17 hydrophobic
residues (Ile 239
 
®
 
Phe 255) presents a potential trans-
membrane region, and there are 45 residues in the cyto-
plasmic domain. The extracellular portion contains two
domains with intrachain disulfide bonds typical of immu-
noglobulin-like loops of the V-type (see the schematic rep-
resentation in Fig. 5 
 
B
 
; 8, 29). The difference between the
predicted protein of 32 kD and that observed with immu-
noprecipitation indicated that the 
 
N
 
-linked glycosylation
sites are used by the cells. In fact, when cells were treated
with tunicamycin (1 mg/ml overnight), the band immuno-
precipitated by BV11 was thinner and shifted to 
 
z
 
29 kD,
which corresponds to the predicted molecular mass of the
core protein (data not shown). COS cells transfected with
the BV11 cDNA synthesized a protein that could be im-
munoprecipitated by BV11 mAb, and showed a molecular
mass comparable to that found in EC. Northern blot anal-
ysis of organ extracts showed one species of RNA of 
 
z
 
2
kb (Fig. 4 
 
B
 
) in mouse lung, spleen, brain, and heart.
 
Transfected BV11 Antigen Clusters at Intercellular 
Junctions and Promotes Cell–Cell Adhesion 
 
When BV11 antigen was transfected in CHO cells as re-
ported in Fig. 6 
 
B
 
 (10), it concentrated at intercellular
junctions in confluent cultures. In sparse cells, the antigen
was found only in the areas of cell–cell contacts, and re-
mained diffuse or absent at free cell borders (Fig. 6 
 
A
 
). In
mixed cultures of BV11 and control transfectants, BV11
antigen did not concentrate at intercellular junctions when
transfected cells were in contact with control transfectants
(not shown).
To evaluate the ability of BV11 to promote intercellular
adhesion, we measured the paracellular permeability of
transfectant monolayers using Transwell filters in vitro
(10). CHO cells are particularly suitable for this assay
Figure 1. Immunofluores-
cence analysis of the cellular
distribution of BV11 antigen,
ZO-1, and VE-cadherin in
cultured EC (H5V) mono-
layers (A–C), and of BV11
and cingulin in a section of a
small artery of the liver (D–
F). In cultured EC, BV11 an-
tigen distribution (A) shows
a cell–cell contact pattern
similar to that shown with
ZO-1 (B) and VE-cadherin
(C). In artery cryosections, at
confocal double-label immu-
nofluorescence microscopy,
BV11 antigen (red fluores-
cence;  E) distributed at cell–
cell contacts in a way similar
to cingulin (green fluores-
cence; D). In merging (F),
BV11 antigen staining
showed colocalization with
cingulin in few areas (yellow
fluorescence; F). Bar, 5 mm.Martin-Padura et al. A Novel Protein at Cell–Cell Junctions 121
since untransfected cells do not express cadherins (10) or
organized TJ (I. Martìn-Padura, unpublished observa-
tions). As shown in Fig. 6 C, paracellular permeability was
reduced by 50% in BV11 transfectants, and this activity
was inhibited in the presence of EGTA. Adding EGTA to
control CHO cells did not modify permeability. As a com-
parison, paracellular permeability was reduced in VE -and
N-cadherin CHO transfectants in a way comparable to
JAM transfectants. In contrast, permeability remained un-
affected in transfectants expressing a mutant of VE-cad-
herin lacking the cytoplasmic domain responsible for cate-
nin binding (39). Truncated VE-cadherin is correctly
expressed on CHO cell membrane in amounts comparable
to the wild-type form (39). This last result confutes the
possibility that reduction in paracellular permeability is an
unspecific consequence of CHO transfection with mem-
brane associated proteins.
Overall, these data suggest that BV11 promotes cell–cell
adhesion. For this property and for its localization at junc-
tions we propose the name JAM (junctional adhesion mol-
ecule) for the BV11 antigen.
Another mAb, BV12, raised against H5V endothelial
cells, was found to recognize the same antigen by immuno-
precipitation analysis and ELISA on JAM recombinant
fragments (see Materials and Methods), H5V, and CHO
transfected with JAMcDNA (not shown). As reported in
Fig. 7, this mAb, similarly to BV11, decorated cell–cell
contacts in endothelial and epithelial cells and in CHO
JAM transfectants.
mAb BV11 Inhibits Monocyte Transmigration Through 
Endothelial Cell Monolayers
The distribution and structural data suggest the possibility
that JAM, similarly to PECAM-1, could play a role in leu-
kocyte transmigration. We therefore tested this possibility.
Figure 2. Immunofluores-
cence analysis of the cellular
BV11 antigen distribution in
cultured epithelial cells (A–
C,  a–c) and in a tissue section
of a mouse duodenum (D–
F). Cultured epithelial cells
(PDV) were costained with
cingulin (green fluorescence;
A, a) and BV11 mAb (red
fluorescence; B, b). Confocal
laser-scanning micrographs
of horizontal (A, B) and ver-
tical (a, b) focal planes, and
merging of the two staining
patterns (yellow fluorescence;
C and c) are shown. BV11
and cingulin codistributed at
the immediate subapical
level of the intercellular cleft.
Thickness of cultured epithe-
lial cells is 5–8 mm. Cryosec-
tions of the epithelium of the
mouse duodenum were co-
stained with b-catenin (D)
and BV11 mAb (E). The
merging of the two staining
patterns is shown in F. BV11
was restricted at the apical
region of the cell junctions,
and did not colocalize with
b-catenin, which was more
diffusely distributed along
the lateral side of the mem-
brane. L, lumen. Bars, 5 mm.
Figure 3. (A and B) Electron
microscopy localization of
BV11 antigen (JAM) on ul-
trathin cryosections of the
epithelium of mouse duode-
num. The gold particles dec-
orated the tight junction (TJ)
area (arrows). The immu-
nogold was absent from ad-
herens junction (zonula
adhaerentes,  ZA) and desmo-
somes (D). Bars, 0.1 mM.The Journal of Cell Biology, Volume 142, 1998 122
As reported in Fig. 8 A, spontaneous monocyte transmi-
gration through EC monolayers was inhibited by the BV11
mAb. This effect was specific since an irrelevant mAb of
the same isotype (MK 2.7, IgG2b) able to bind to EC, an-
other mAb directed to JAM (BV12), or an mAb to CD34
(24) that also concentrates at intercellular contacts, had no
effect. In addition, F(ab9) fragments of BV11 retained in-
hibitory activity. Overall, these data confute the possibility
that nonspecific or Fc-mediated effects of bound mAb are
responsible for the inhibition seen with mAb BV11.
The effect of mAb BV11 was then tested on chemokine-
induced monocyte transmigration. MCP-1 and MCP-3
were used as chemoattractants for their specific activity on
mononuclear cells (53; Fig. 8 B). BV11 was able to reduce
monocyte transmigration induced by MCP-1 and MCP-3
by 42% (P , 0.01) and by 51% (P , 0.01), respectively.
Finally, BV11 was found inhibitory when monocyte
chemotaxis was induced by LPS activation of EC (Fig. 8
C). After stimulating EC for 24 h with LPS (50 ng/ml), a
twofold increase in monocyte transmigration was found.
Treatment with BV11, but not with an irrelevant mAb
IgG2b, blocked transmigation. LPS treatment of EC did
not induce a significant increase in JAM expression as
evaluated by FACS analysis and ELISA (data not shown).
Monocyte adhesion to EC measured as number of cells
that remained bound to the apical surface of the EC plus
transmigrated cells was not modified by BV11 (data not
shown). The lack of effect of BV11 on monocyte adhesion
was further confirmed by adding Cr51-labeled monocytes
to confluent EC in the presence of the antibody, as previ-
ously described (1). BV11 up to a concentration of 5 mg/ml
did not alter spontaneous monocyte adhesion to EC for up
to 60 min of incubation (not shown).
When monocyte chemotaxis to MCP-1 (59) was mea-
sured in Transwell chambers in the absence of EC, BV11
was inactive (not shown). This result excludes the possibil-
ity that the antibody could unspecifically inhibit monocyte
motility and chemotaxis.
mAb BV11 Inhibits Monocyte Infiltration in a Model of 
Skin Inflammation in Mice
We then moved to an in vivo assay of skin inflammatory
reaction in the mouse. The air pouch system was used (18,
44). The treatment scheme is illustrated in Fig. 9 A: MCP-3
was injected in the pouch, and the number of emigrated
mononuclear cells was then evaluated. MCP-3 caused emi-
gration of 1.576 0.39 3 106 cells after 1 h, which is three
times the number obtained after saline (0.49 6 0.19 3 106)
or vehicle (0.58 6 0.38 3 106; carboxymethylcellulose) in-
jection; 70% (6 3%) of the emigrated cells were mono-
cytes. As reported in Fig. 9 B, administration of BV11 to
mice blocked MCP-3–induced mononuclear cell emigra-
tion, while injection of an irrelevant purified mAb of the
same isotype had no effect.
Circulating cell counts (monocytes and neutrophils)
were monitored 30 min after antibody injection and just
before animal death, and showed no significant changes
from baseline.
Table I. Distribution of BV11 Antigen (JAM) in Tissue Sections
Cells Distribution
Endothelial
Endocardium 11
Arteries 11
Arterioles 11
Veins 11
Venules 1
Capillaries 11
High endothelial venules 1
Brain large vessels 11
Brain capillaries 11
Brain penetrating vessels 11
Choroid plexus vessels 11
Blood
Hematopoietic precursors 2
Monocytes 2
Granulocytes 2
Erythrocytes 2
Megakaryocytes 11
Epithelial
Squamous epithelium 11
Skin 11
Oral cavity 11
Esophagus 11
Respiratory epithelium 11
Nasal cavity 11
Trachea 11
Bronchus 11
Intestinal epithelium 11
Renal epithelium 1
Hepatocytes 6
Breast glands 11
Thyroid glands 11
Choroid plexus epithelium 11
Lens epithelium 2
Mesenchymal
Fibroblasts 2
Mesothelial cells 1
Tissue distribution of BV11 mAb was evaluated using immunohistochemistry on cryo-
stat sections from adult mice organs, newborn mice and 14-d fetuses. For details see
Materials and Methods. 6003.
Figure 4. (A) Immunopre-
cipitation analysis of BV11
antigen in different cultured
cells. Biotinylated whole-cell
extracts were obtained from
confluent EC (H5V, lane 1),
epithelial cells (PDV, lane 2),
COS cells transfected with
the full length cDNA of
mouse JAM (lane 3), and
COS cells transfected with
the empty pCDM8 plasmid
(lane  4) and immunoprecipi-
tated as described in Materi-
als and Methods, showing a
single band of 36–41 kD un-
der reduced conditions. Mi-
gration of molecular weight
markers is reported on the
left. (B) Northern blot analysis of mRNA expression in different
murine organs: lung (lane 1), spleen (lane 2), brain (lane 3), and
heart (lane 4). Migration of the molecular mass markers is indi-
cated on the left.Martin-Padura et al. A Novel Protein at Cell–Cell Junctions 123
Discussion
In this study we have identified and cloned a new member
of the IgSF that localizes at intercellular junctions in the
epithelium and endothelium of different origins. For its
type of cellular distribution and its adhesive properties
(see below), we propose for this newly described protein
the name JAM, junctional adhesion molecule.
At a molecular level, JAM is a type I integral membrane
protein and presents, at the extracellular region, two do-
mains with intrachain disulfide bonds typical of Ig loops of
the V-type. Searches of available DNA and protein data
bases revealed no direct sequence similarities with any
known protein with the exception of A33 antigen, which is
a recently cloned intestine-specific Ig protein (30). The V-V
is a novel arrangement of Ig domains, and JAM is not a
member of any subfamily of the IgSF (8).
The distribution of two anti JAM mAbs (BV11 and
BV12) in cultured endothelial and epithelial cells shows
strict localization at cell–cell contacts. At confocal and im-
munoelectron microscopy in cell culture and in vivo sec-
tions, JAM is found to be concentrated at the apical region
of intercellular junctions in correspondence to TJ. In addi-
tion, codistribution with TJ markers such as cingulin or oc-
cludin can be observed.
JAM cDNA transfection into CHO cells leads to local-
ization of the protein at cell–cell contacts. This localization
is apparent only in confluent monolayers and when neigh-
boring cells express JAM. In mixed cultures when JAM
transfectants are in contact with control transfectants, the
protein remains diffuse, indicating that JAM clustering is
due to homotypic interaction.
JAM expression reduces the paracellular permeability
of cell monolayers, suggesting that this molecule promotes
cell–cell adhesion. In the same experimental system, other
molecules known to mediate homophilic adhesion such as
VE- or N-cadherin induce a similar reduction in paracellu-
lar permeability when transfected in CHO cells. This ef-
Figure 5. (A) Nucleotide and
deduced amino acid sequence of
murine BV11 antigen (JAM)
cDNA. The putative hydropho-
bic signal peptide (dotted under-
lined) and transmembrane se-
quences (underlined) are
marked. Potential N-linked glyc-
osylation sites are marked in
bold and underlined at posi-
tions 42 and 185. Putative phos-
phorylation sites are marked in
bold. Cysteines likely to form
disulfide bonds in the two Ig do-
mains (V-type) are boxed. These
sequence data are available from
GenBank, European Molecular
Biology Laboratory, and DNA
Data Base of Japan under the
accession code U89915. (B) Struc-
tural model for murine JAM. The
extracellular portion contains two
domains with intrachain disulfide
bonds typical of immunoglobu-
lin-like loops of the V-type. Two
putative  N-linked  glycosylation
sites (—d) are shown.The Journal of Cell Biology, Volume 142, 1998 124
fect seems specific since transfection of a truncated mutant
of VE-cadherin that was expressed on the cell membrane
with an efficiency comparable to that of the wild-type
form (39) was ineffective.
In contrast to these findings, in preliminary experiments
JAM-CHO transfectants did not aggregate in suspension
(not shown). A possible explanation for this discrepancy is
that detachment of the cells could alter JAM conforma-
tion and/or cause a slight digestion of biologically active
epitopes so that the molecule loses its adhesive properties.
Interestingly, VE-cadherin presents a similar behavior
since it is poorly active in promoting homotypic aggrega-
tion of cells in suspension, but significantly reduces para-
cellular permeability (10). For VE-cadherin, the effect on
permeability requires its anchorage to catenins and the ac-
tin cytoskeleton since a truncated mutant of the molecule
is ineffective (39 and the present paper). We still do not
know whether JAM is linked to the cell cytoskeleton or
whether this association is required for its adhesive activ-
ity. If this requirement for JAM association to the cyto-
skeleton is the case, it is possible that when cells are in sus-
pension and the organization of the cytoskeleton is
modified, JAM activity is inhibited.
The distribution of JAM at TJ tempts us to speculate
that this protein participates in the assembly and organiza-
tion of these structures, and directly interacts with TJ com-
ponents. However, further studies are required to prove
this possibility directly.
When compared with occludin, JAM presents a differ-
ent biological behavior. It has been reported that trans-
fected occludin concentrates at intercellular junctions and
confers adhesion mostly in cells that already express orga-
nized AJ or TJ (6, 54). JAM seems to act independently
from preorganized junctional structures. The CHO cells
used in this work do not express cadherins (10), and do not
present organized TJ at electron microscopy (I. Martìn-
Padura, unpublished results). However, when transfected
with JAM, the cells are able to concentrate this protein at
intercellular contacts. This behavior is similar to that of
other junctional proteins such as PECAM or VE-cadherin.
Figure 6. Immunofluorescence analysis of BV11
mAb distribution in CHO cells transfected with
JAM, and evaluation of paracellular permeabil-
ity of transfectant monolayers. In sparse JAM-
CHO cells the BV11 staining pattern is restricted
to the areas of cell–cell contacts (A), while in
confluent monolayers BV11 mAb distributed all
along the intercellular junctions (B). Permeabil-
ity of control CHO cell monolayers (pECE-CHO)
to FITC-dextran was reduced by JAM transfection
(JAM-CHO), and adding EGTA (JAM-
CHO1EGTA) abolished this difference (C).
EGTA did not modify permeability of control
CHO cells (pECE-CHO1EGTA). Transfection
of VE-cadherin (VE-CAD) and N-cadherin (N-
CAD) reduced paracellular permeability in a
way similar to JAM transfection. In contrast,
transfection of truncated VE-cadherin (tVE-
CAD) was ineffective. Samples from three dif-
ferent wells from three independent experiments
were grouped. Overlapping results were obtained
when similar experiments were performed with
three other independent clones of control and
transfectant cells.
Figure 7. Immunofluorescence analysis of BV12 mAb distribu-
tion in CHO cells transfected with JAM (A), control CHO cells
(B), H5V endothelial cells (C), and PDV epithelial cells (D).
Similarly to BV11 (see Figs. 1, 2, and 6), BV12 staining pattern is
restricted to the areas of cell–cell contacts in all the cells express-
ing JAM. Bar, 5 mm.Martin-Padura et al. A Novel Protein at Cell–Cell Junctions 125
It is possible that JAM participates in the first steps of in-
tercellular contact formation through homophilic cluster-
ing, and that only a second time gets incorporated in TJ.
A major finding of the present study is that a JAM
mAb, BV11, was able to inhibit monocyte transmigration
through endothelial monolayers in vitro and to block
monocyte infiltration in a skin inflammatory model in
vivo.
This effect was not mediated by unspecific Fc receptor
binding since F(ab9) fragments of the mAb retain the ac-
tivity, and since another mAb of the same isotype able to
bind EC was inactive. In addition, the effect was specific
for BV11 since another available mAb directed to JAM
(BV12), but recognizing a different epitope (see Materials
and Methods), was ineffective.
BV11 inhibited not only spontaneous monocyte trans-
migration but also transmigration induced by adding
monocyte-specific chemokines (MCP-1 or MCP-3) or by
activating the endothelial cell monolayers with LPS. This
result suggests that BV11 exerts a specific and general ef-
fect on transmigration. Indeed, BV11 does not influence
monocyte chemotaxis through empty filters, and does not
change monocyte adhesion to endothelial cells, indicating
that its activity is not due to inhibition of monocyte reac-
tivity to chemokines or to adhesion molecules.
The data obtained in vitro using chemotaxis assays were
confirmed in an in vivo model of skin inflammation. In this
model the mAb BV11 was strongly effective, and essen-
tially blocked monocyte transmigration to MCP-3. The ef-
fect of the mAb seems specific since the same dose of an
irrelevant mAb of the same isotype was ineffective.
Figure 8. Effect of JAM anti-
bodies on transendothelial
migration of monocytes in
vitro. (A) Spontaneous mono-
cyte migration across EC
monolayers in vitro is inhib-
ited by mAb BV11 (IgG and
F(ab9) fragments), but not by
anti-JAM mAb BV12 nor
anti-CD34 (MEC 14) mAb.
An irrelevant mAb (MK
2.7) of the same isotype
(IgG2b) of BV11 was also in-
active. (B) Anti-JAM mAb
BV11 blocks spontaneous
(open bars), MCP-1 (100 ng/
ml; hatched bars), and MCP-3
(100 ng/ml)–induced migration (solid bars) of monocytes across EC monolayers in vitro. (C) mAb BV11 inhibited monocyte transmi-
gration through LPS-treated EC monolayers. EC were incubated with LPS (50 ng/ml) for 24 h, and were then washed before monocyte
addition as described. Data are mean of at least three experiments performed in quadruplicates. Error bars, SD. *P , 0.001 by analysis
of variance and Dunnett’s test in comparison to values obtained in absence of antibodies.
emigration in the air pouch model in vivo. The figure reports the
results of typical experiments out of at least three performed.
Error bars, SD. *P , 0.001 by analysis of variance and Dunnett’s
test in comparison to values obtained in the absence of antibodies.
Figure 9. (A) Treatment scheme of the air pouch model of skin
inflammation in mice. Two different volumes of air were injected
subcutaneously in the animals at 3-d intervals. BV11 or an irrele-
vant purified mAb (HB151) of the same isotype or saline were
administered intravenously (i.v.) 60 h after the second air injec-
tion. 12 h later MCP-3 was injected intrapouch. After 1 h mice
were killed, and the pouches were washed with 1 ml of saline.
Mononuclear cells present were stained with erythrosin and
counted.  (B) Effect of BV11 mAb on MCP-3–induced monocyteThe Journal of Cell Biology, Volume 142, 1998 126
In addition, mice deficient of the complement compo-
nent C1q (58) were equally responsive to mAb BV11 (M.
Romano and P. Fruscella, unpublished data), excluding in
this way a role of complement activation in the observed
inhibition.
The mechanism of action of mAb BV11 and of JAM in
general is still unknown. A possibility is that JAM, for its
localization at intercellular contacts, binds monocytes and
directs their migration through the intercellular cleft.
Other proteins such as the matrix protein hevin have been
suggested to modulate transendothelial migration of lym-
phocytes by facilitating their motility (27). A similar mech-
anism has also been hypothesized for another junctional
immunoglobin such as PECAM-1, which is located in a
less apical domain of the interendothelial cleft (5). PE-
CAM is unable to induce leukocyte adhesion, but appears
to be required for their extravasation (38). It is possible
that these two proteins collaborate in promoting cell
movement through the interendothelial junctions by act-
ing at different regions of the intercellular cleft.
An important question is related to JAM counterrecep-
tor on monocytes. mAb BV11 does not recognize mono-
cytes, and does not change endothelial cell or JAM-CHO
transfectant paracellular permeability, strongly suggesting
that this mAb does not exert its activity by inhibiting ho-
motypic binding. It is conceivable that monocytes recog-
nize this protein through a heterotypic type of interaction
inhibited by mAb BV11. Other immunoglobulins, includ-
ing PECAM, have been found to express both homophilic
and heterophilic types of interactions (32).
In conclusion, in this paper we report the identification
and cloning of a new member of the immunoglobulin fam-
ily with a so far undescribed V-V structure that we called
JAM. This protein concentrates at endothelial and epithe-
lial junctions, and codistributes with TJ components. The
mAb BV11 directed to JAM inhibits monocyte transmi-
gration in vitro and in vivo, strongly suggesting that this
molecule is relevant in the control of monocyte infiltration
in inflammatory conditions.
The mechanism of action of JAM requires further inves-
tigation, but the data reported strongly support the con-
cept that manipulation of the molecular organization of
endothelial junctions could be an effective approach in
controlling endothelial permeability and monocyte traffic.
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